The most attractive part of WAVE.V is share structure: 54M total float with 41M shares held by insiders / escrowed, leaving about 13M shares free trading. The company owns a portfolio of generic oncology drugs from which it generates over $300K of quarterly revenue. $1M in cash on hand. Based on last financials, they are $83K away from generating positive cash...
Big jump in this little known Canadian pharma's stock price this morning on news of market authorization of their drugs in multiple European countries. Tiny float makes for big moves up and down. Good speculative buy on pullback in the .20s, IMO.
Waverley Pharma Announces Grant of Market Authorization for Pemetrexed and Bortezomib in Multiple European...
